Gilead Gains European Approval To Market Combination Antiretroviral Drug Truvada
Foster City, Calif.-based biotech company Gilead on Wednesday received approval from the European Commission to market its combination antiretroviral drug Truvada in all 25 European Union countries, the AP/Forbes reports. Truvada is a once-daily combination pill containing the antiretroviral drugs Emtriva and Viread, known generically as emtricitabine and tenofovir, respectively. The drugs work by blocking HIV's reverse transcriptase enzyme to prevent viral replication (AP/Forbes, 2/23). The drug was approved for marketing in the United States in August 2004, according to San Francisco Business Times (San Francisco Business Times, 2/23).
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
